210 related articles for article (PubMed ID: 28928122)
1. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia.
Ariazi JL; Duffy KJ; Adams DF; Fitch DM; Luo L; Pappalardi M; Biju M; DiFilippo EH; Shaw T; Wiggall K; Erickson-Miller C
J Pharmacol Exp Ther; 2017 Dec; 363(3):336-347. PubMed ID: 28928122
[TBL] [Abstract][Full Text] [Related]
2. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
Holdstock L; Meadowcroft AM; Maier R; Johnson BM; Jones D; Rastogi A; Zeig S; Lepore JJ; Cobitz AR
J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
[TBL] [Abstract][Full Text] [Related]
3. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Shinozaki Y; Fukui K; Kobayashi H; Yoshiuchi H; Matsuo A; Matsushita M
Eur J Pharmacol; 2021 May; 898():173990. PubMed ID: 33657422
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.
Katagiri N; Hitomi H; Mae SI; Kotaka M; Lei L; Yamamoto T; Nishiyama A; Osafune K
Sci Rep; 2021 Feb; 11(1):3936. PubMed ID: 33594180
[TBL] [Abstract][Full Text] [Related]
5. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
Nakai T; Saigusa D; Kato K; Fukuuchi T; Koshiba S; Yamamoto M; Suzuki N
Life Sci; 2024 Jun; 346():122641. PubMed ID: 38614299
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
Packer M
Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for binding of the renal carcinoma target hypoxia-inducible factor 2α to prolyl hydroxylase domain 2.
Figg WD; Fiorini G; Chowdhury R; Nakashima Y; Tumber A; McDonough MA; Schofield CJ
Proteins; 2023 Nov; 91(11):1510-1524. PubMed ID: 37449559
[TBL] [Abstract][Full Text] [Related]
8. A Single-Dose, Open-Label, Randomized, Two-Way Crossover Study in Healthy Japanese Participants to Evaluate the Bioequivalence and the Food Effect on the Pharmacokinetics of Daprodustat.
Yamada M; Osamura M; Ogura H; Onoue T; Wakamatsu A; Numachi Y; Caltabiano S; Mahar KM
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):978-984. PubMed ID: 32250021
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of the sensory and regulatory pathways controlling cellular iron metabolism in unilateral obstructive nephropathy.
Votava JA; Reese SR; Deck KM; Nizzi CP; Anderson SA; Djamali A; Eisenstein RS
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F89-F103. PubMed ID: 34843656
[TBL] [Abstract][Full Text] [Related]
10. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases.
Chowdhury R; Leung IK; Tian YM; Abboud MI; Ge W; Domene C; Cantrelle FX; Landrieu I; Hardy AP; Pugh CW; Ratcliffe PJ; Claridge TD; Schofield CJ
Nat Commun; 2016 Aug; 7():12673. PubMed ID: 27561929
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-inducible factor prolyl-4-hydroxylation in FOXD1 lineage cells is essential for normal kidney development.
Kobayashi H; Liu J; Urrutia AA; Burmakin M; Ishii K; Rajan M; Davidoff O; Saifudeen Z; Haase VH
Kidney Int; 2017 Dec; 92(6):1370-1383. PubMed ID: 28847650
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
Beck H; Jeske M; Thede K; Stoll F; Flamme I; Akbaba M; Ergüden JK; Karig G; Keldenich J; Oehme F; Militzer HC; Hartung IV; Thuss U
ChemMedChem; 2018 May; 13(10):988-1003. PubMed ID: 29485740
[TBL] [Abstract][Full Text] [Related]
15. Gamma-Aminobutyric Acid Increases Erythropoietin by Activation of Citrate Cycle and Stimulation of Hypoxia-Inducible Factors Expression in Rats.
Park KT; Han JK; Kim SJ; Lim YH
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32290638
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of hepatic EPO synthesis in mice after PHD loss.
Minamishima YA; Kaelin WG
Science; 2010 Jul; 329(5990):407. PubMed ID: 20651146
[TBL] [Abstract][Full Text] [Related]
17. Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates.
Cockman ME; Lippl K; Tian YM; Pegg HB; Figg WD; Abboud MI; Heilig R; Fischer R; Myllyharju J; Schofield CJ; Ratcliffe PJ
Elife; 2019 Sep; 8():. PubMed ID: 31500697
[TBL] [Abstract][Full Text] [Related]
18. Effects of Roxadustat on Erythropoietin Production in the Rat Body.
Yasuoka Y; Izumi Y; Fukuyama T; Omiya H; Pham TD; Inoue H; Oshima T; Yamazaki T; Uematsu T; Kobayashi N; Shimada Y; Nagaba Y; Yamashita T; Mukoyama M; Sato Y; Wall SM; Sands JM; Takahashi N; Kawahara K; Nonoguchi H
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164384
[TBL] [Abstract][Full Text] [Related]
19. Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor.
Wang RX; Henen MA; Lee JS; Vögeli B; Colgan SP
Gut Microbes; 2021; 13(1):1938380. PubMed ID: 34190032
[TBL] [Abstract][Full Text] [Related]
20. Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study.
Watanabe K; Sato E; Mishima E; Moriya S; Sakabe T; Sato A; Fujiwara M; Fujimaru T; Ito Y; Taki F; Nagahama M; Tanaka K; Kazama JJ; Nakayama M
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
